Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Angelo Avogaro and Gian Fadini.
Angelo Avogaro
Connection Strength
19.859
Gian Fadini
  1. Managing diabetes in diabetic patients with COVID: where do we start from? Acta Diabetol. 2021 Nov; 58(11):1441-1450.
    View in: PubMed
    Score: 0.953
  2. Exposure to dipeptidyl-peptidase-4 inhibitors and COVID-19 among people with type 2 diabetes: A case-control study. Diabetes Obes Metab. 2020 10; 22(10):1946-1950.
    View in: PubMed
    Score: 0.890
  3. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. 2020 06; 43(6):867-869.
    View in: PubMed
    Score: 0.874
  4. Angiogenic Abnormalities in Diabetes Mellitus: Mechanistic and Clinical Aspects. J Clin Endocrinol Metab. 2019 11 01; 104(11):5431-5444.
    View in: PubMed
    Score: 0.850
  5. Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study. J Am Heart Assoc. 2019 07 16; 8(14):e012244.
    View in: PubMed
    Score: 0.831
  6. The pleiotropic cardiovascular effects of dipeptidyl peptidase-4 inhibitors. Br J Clin Pharmacol. 2018 08; 84(8):1686-1695.
    View in: PubMed
    Score: 0.771
  7. Pharmacovigilance Evaluation of the Association Between DPP-4 Inhibitors and Heart Failure: Stimulated Reporting and Moderation by Drug Interactions. Diabetes Ther. 2018 Apr; 9(2):851-861.
    View in: PubMed
    Score: 0.759
  8. Insulin treatment in patients with diabetes and heart failure: defendant on the stand. Eur J Heart Fail. 2018 05; 20(5):896-897.
    View in: PubMed
    Score: 0.758
  9. Effects of Hypoglycemia on Circulating Stem and Progenitor Cells in Diabetic Patients. J Clin Endocrinol Metab. 2018 03 01; 103(3):1048-1055.
    View in: PubMed
    Score: 0.757
  10. Counterpoint to the hypothesis that SGLT2 inhibitors protect the heart by antagonizing leptin. Diabetes Obes Metab. 2018 Jun; 20(6):1367-1368.
    View in: PubMed
    Score: 0.756
  11. The impact of glucose-lowering medications on cardiovascular disease. Cardiovasc Endocrinol Metab. 2018 Mar; 7(1):13-17.
    View in: PubMed
    Score: 0.755
  12. How to interpret the role of SDF-1a on diabetic complications during therapy with DPP-4 inhibitors. Cardiovasc Diabetol. 2018 02 02; 17(1):22.
    View in: PubMed
    Score: 0.753
  13. Glucagon-like peptide-1 receptor agonists are not associated with retinal adverse events in the FDA Adverse Event Reporting System. BMJ Open Diabetes Res Care. 2018; 6(1):e000475.
    View in: PubMed
    Score: 0.753
  14. p66Shc gene expression in peripheral blood mononuclear cells and progression of diabetic complications. Cardiovasc Diabetol. 2018 01 17; 17(1):16.
    View in: PubMed
    Score: 0.751
  15. Dipeptidyl peptidase-4 inhibitors moderate the risk of genitourinary tract infections associated with sodium-glucose co-transporter-2 inhibitors. Diabetes Obes Metab. 2018 03; 20(3):740-744.
    View in: PubMed
    Score: 0.742
  16. SGLT2 inhibitors and amputations in the US FDA Adverse Event Reporting System. Lancet Diabetes Endocrinol. 2017 09; 5(9):680-681.
    View in: PubMed
    Score: 0.725
  17. SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System. Diabetologia. 2017 08; 60(8):1385-1389.
    View in: PubMed
    Score: 0.716
  18. Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial. Cardiovasc Diabetol. 2017 04 04; 16(1):42.
    View in: PubMed
    Score: 0.711
  19. Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes. J Clin Endocrinol Metab. 2016 Feb; 101(2):748-56.
    View in: PubMed
    Score: 0.650
  20. Role of endothelial progenitor cells in diabetes mellitus. Expert Rev Endocrinol Metab. 2009 Nov; 4(6):575-589.
    View in: PubMed
    Score: 0.425
  21. Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis. J Endocrinol Invest. 2021 Jul; 44(7):1379-1386.
    View in: PubMed
    Score: 0.232
  22. The Toll of Lockdown Against COVID-19 on Diabetes Outpatient Care: Analysis From an Outbreak Area in Northeast Italy. Diabetes Care. 2021 01; 44(1):e18-e21.
    View in: PubMed
    Score: 0.228
  23. Hyperglycemia, glucocorticoid therapy, and outcome of COVID-19. Diabetes Res Clin Pract. 2020 10; 168:108449.
    View in: PubMed
    Score: 0.226
  24. Newly-diagnosed diabetes and admission hyperglycemia predict COVID-19 severity by aggravating respiratory deterioration. Diabetes Res Clin Pract. 2020 Oct; 168:108374.
    View in: PubMed
    Score: 0.224
  25. Glycaemic Control Among People with Type 1 Diabetes During Lockdown for the SARS-CoV-2 Outbreak in Italy. Diabetes Ther. 2020 Jun; 11(6):1369-1379.
    View in: PubMed
    Score: 0.220
  26. Pharmacovigilance assessment of the association between Fournier's gangrene and other severe genital adverse events with SGLT-2 inhibitors. BMJ Open Diabetes Res Care. 2019; 7(1):e000725.
    View in: PubMed
    Score: 0.211
  27. Fixed versus flexible combination of GLP-1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study. Diabetes Obes Metab. 2019 11; 21(11):2542-2552.
    View in: PubMed
    Score: 0.209
  28. Effects of exenatide long-acting release on cardiovascular events and mortality in patients with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2019 Sep; 56(9):1051-1060.
    View in: PubMed
    Score: 0.205
  29. Effects of SGLT2 Inhibitors on Circulating Stem and Progenitor Cells in Patients With Type 2 Diabetes. J Clin Endocrinol Metab. 2018 10 01; 103(10):3773-3782.
    View in: PubMed
    Score: 0.197
  30. Effectiveness of dapagliflozin versus comparators on renal endpoints in the real world: A multicentre retrospective study. Diabetes Obes Metab. 2019 02; 21(2):252-260.
    View in: PubMed
    Score: 0.197
  31. Phenotyping normal kidney function in elderly patients with type 2 diabetes: a cross-sectional multicentre study. Acta Diabetol. 2018 Nov; 55(11):1121-1129.
    View in: PubMed
    Score: 0.195
  32. Exposure to insulin degludec during pregnancy: report of a small series and review of the literature. J Endocrinol Invest. 2019 Mar; 42(3):345-349.
    View in: PubMed
    Score: 0.195
  33. Comparative Effectiveness of DPP-4 Inhibitors Versus Sulfonylurea for the Treatment of Type 2 Diabetes in Routine Clinical Practice: A Retrospective Multicenter Real-World Study. Diabetes Ther. 2018 Aug; 9(4):1477-1490.
    View in: PubMed
    Score: 0.193
  34. Characteristics, prevalence, and outcomes of diabetic foot ulcers in Africa. A systemic review and meta-analysis. Diabetes Res Clin Pract. 2018 Aug; 142:63-73.
    View in: PubMed
    Score: 0.192
  35. Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective study. Diabetes Obes Metab. 2018 07; 20(7):1781-1786.
    View in: PubMed
    Score: 0.190
  36. The antidiabetic drug metformin blunts NETosis in vitro and reduces circulating NETosis biomarkers in vivo. Acta Diabetol. 2018 Jun; 55(6):593-601.
    View in: PubMed
    Score: 0.190
  37. Interplay between gut microbiota and p66Shc affects obesity-associated insulin resistance. FASEB J. 2018 07; 32(7):4004-4015.
    View in: PubMed
    Score: 0.189
  38. Shift of monocyte subsets along their continuum predicts cardiovascular outcomes. Atherosclerosis. 2017 Nov; 266:95-102.
    View in: PubMed
    Score: 0.184
  39. Rationale and design of the DARWIN-T2D (DApagliflozin Real World evIdeNce in Type 2 Diabetes): A multicenter retrospective nationwide Italian study and crowdsourcing opportunity. Nutr Metab Cardiovasc Dis. 2017 Dec; 27(12):1089-1097.
    View in: PubMed
    Score: 0.182
  40. Sodium-glucose co-transporter-2 inhibitors and diabetic ketoacidosis: An updated review of the literature. Diabetes Obes Metab. 2018 01; 20(1):25-33.
    View in: PubMed
    Score: 0.181
  41. Persistent Reduction of Circulating Myeloid Calcifying Cells in Acromegaly: Relevance to the Bone-Vascular Axis. J Clin Endocrinol Metab. 2017 06 01; 102(6):2044-2050.
    View in: PubMed
    Score: 0.180
  42. Intraclass differences in the risk of hospitalization for heart failure among patients with type 2 diabetes initiating a dipeptidyl peptidase-4 inhibitor or a sulphonylurea: Results from the OsMed Health-DB registry. Diabetes Obes Metab. 2017 10; 19(10):1416-1424.
    View in: PubMed
    Score: 0.180
  43. Reduced circulating stem cells associate with excess fasting and post-load NEFA exposure in healthy adults with normal glucose tolerance. Atherosclerosis. 2017 06; 261:117-123.
    View in: PubMed
    Score: 0.177
  44. Lung Ultrasound Patterns and Clinical-Laboratory Correlates during COVID-19 Pneumonia: A Retrospective Study from North East Italy. J Clin Med. 2021 Mar 20; 10(6).
    View in: PubMed
    Score: 0.058
  45. miR-30c-5p regulates macrophage-mediated inflammation and pro-atherosclerosis pathways. Cardiovasc Res. 2017 Nov 01; 113(13):1627-1638.
    View in: PubMed
    Score: 0.046
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.